FDA user fee date for King's Embeda passes without action
This article was originally published in Scrip
The US FDA's review ofKing Pharmaceuticals' (formerly Alpharma's) Embeda, a modified-released formulation of morphine coupled with the opioid antagonist naltrexone, has been extended beyond the late December user fee date. "Our discussions with the FDA continue to progress, and we remain confident in the strength of our regulatory submission," King chief science officer Eric Carter said. In November an FDA advisory panel said Embeda provided an incremental improvement over existing controlled-release morphine products because it appeared to be less susceptible to abuse and misuse (Scrip Online, November 17th, 2008). However, the panel called for more data on potential abuse through intravenous injection, snorting and chewing, and a risk evaluation and mitigation strategy (REMS) is needed for approval. King gained Embeda through its recent acquisition of Alpharma.
You may also be interested in...
FDA's recommendation that COVID-19 vaccine sponsors conduct two months of median follow-up to support an emergency use authorization may not be long enough, some experts say in what can be viewed as validation for agency's position in battle with White House.
There are 18 people on the committee that will issue the first recommendations on COVID-19 vaccine development and licensure. Among the experts are a University of Michigan epidemiologist who will serve as acting chairman and seven temporary voting members, two of whom required conflict-of-interest waivers.
Unlike AMAG's Makena, nearly all the products that have seen their accelerated approvals pulled have left the market quietly, our infographic shows.